Last reviewed · How we verify
Hydrochlorothiazide (HCTZ) — Competitive Intelligence Brief
marketed
Thiazide diuretic
Sodium-chloride cotransporter (NCC)
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Hydrochlorothiazide (HCTZ) (Hydrochlorothiazide (HCTZ)) — Novartis. Hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted tubule of the kidney, promoting water and electrolyte excretion to reduce blood volume and blood pressure.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Hydrochlorothiazide (HCTZ) TARGET | Hydrochlorothiazide (HCTZ) | Novartis | marketed | Thiazide diuretic | Sodium-chloride cotransporter (NCC) | |
| olmesartan medoxomil-hydrochlorothiazide | OLMESARTAN | Cosette | marketed | Thiazide Diuretic [EPC] | 2019-01-01 | |
| Benicar | OLMESARTAN MEDOXOMIL | Cosette | marketed | Thiazide Diuretic [EPC] | Type-1 angiotensin II receptor | 2002-01-01 |
| Zestril | lisinopril | Generic (originally Merck/AstraZeneca) | marketed | Thiazide Diuretic [EPC] | Angiotensin-converting enzyme, Angiotensin-converting enzyme | 1987-12-29 |
| Capozide 25/15 | CAPTOPRIL | Aarxion Anda Hlding | marketed | Thiazide Diuretic [EPC] | Renin | 1981-01-01 |
| TRIAMTERENE | TRIAMTERENE | marketed | Thiazide Diuretic [EPC] | 1964-01-01 | ||
| Enduron | methylclothiazide | marketed | Thiazide Diuretic | Solute carrier family 12 member 3 | 1960-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Zestril · 9616096 · Method of Use · US
- — Zestril · 10039800 · Method of Use · US
- — Zestril · 10406199 · Method of Use · US
- — Zestril · 12433931 · Method of Use · US
- — Zestril · 10265370 · Formulation · US
- — Zestril · 9463183 · Formulation · US
- — Zestril · 11179434 · Formulation · US
- — Zestril · 9814751 · Formulation · US
- — Zestril · 10940177 · Formulation · US
- — Zestril · 11771733 · Formulation · US
- — Zestril · 12186360 · Formulation · US
- — Zestril · 12128083 · Formulation · US
Sponsor landscape (Thiazide diuretic class)
- Cedars-Sinai Medical Center · 2 drugs in this class
- National University of Ireland, Galway, Ireland · 1 drug in this class
- Bristol-Myers Squibb · 1 drug in this class
- Seiji Umemoto, M.D., Ph.D. · 1 drug in this class
- Takeda · 1 drug in this class
- University of Virginia · 1 drug in this class
- Novartis · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Hydrochlorothiazide (HCTZ) CI watch — RSS
- Hydrochlorothiazide (HCTZ) CI watch — Atom
- Hydrochlorothiazide (HCTZ) CI watch — JSON
- Hydrochlorothiazide (HCTZ) alone — RSS
- Whole Thiazide diuretic class — RSS
Cite this brief
Drug Landscape (2026). Hydrochlorothiazide (HCTZ) — Competitive Intelligence Brief. https://druglandscape.com/ci/hydrochlorothiazide-hctz. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab